Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Dow Jones, a News Corp company News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services
There’s only one easy way for ordinary investors to track this powerful indicator…The chart below shows how a company's share price and consensus price target have changed over time.
These stocks have paid out triple-digit gains… On the same date… Year after year — for the last decade (look at this week’s Primetime Stock here)MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
Axsome Therapeutics stock price target raised to $140 from $100 at SunTrust RH Dec. 31, 2019 at 8:01 a.m. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders.
Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts. See Axsome Therapeutics, Inc. (AXSM) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The high price target for AXSM is $210.00 and the low price target for AXSM is $48.00.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Short sellers are betting that the stock they sell will decline in price. AXSM updated stock price target summary.
Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts.
There are currently 9 buy ratings for the stock, resulting in a consensus rating of "Buy." View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Based on analysts offering 12 month price targets for AXSM in the last 3 months. One indicator is far more accurate -- but less than 1 in 1,000 investors have ever heard of it.
Decline in budget deficit tied to increase in delayed April tax payments Learn about financial terms, types of investments, trading strategies and more.MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).